Notícias e Atividades da Infant Bacterial Therapeutics

Infant Bacterial Therapeutics pertence à BioGaia.

BioGaia é uma empresa listada sob o símbolo BIOGB (SE).

Eles estão dentro:

• Biotecnologia50%
• Farmacêutica50%

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Infant Bacterial Therapeutics

• Staffan Stromberg, Chief Executive Officer
• Margareta Hagman, Director
• Kristina Nygren, Board Member

Criar um alerta
para seguir os movimentos de executivos da Infant Bacterial Therapeutics.

BioGaia possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Eli Lilly (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).
• Jazz Pharmaceuticals adquiriu Chimerix (publicado em 6 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Infant Bacterial Therapeutics

• IBT | IBT is granted Breakthrough Therapy Designation for its Drug Candidate
• IBT | Infant Bacterial Therapeutics AB publishes the Annual Report for 2024
• IBT | Infant Bacterial Therapeutics AB (publ) Year-end report January 1 – December 31, 2024
• IBT | IBT Continues Development of Drug Candidate IBP-9414
• IBT | Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
• IBT | Infant Bacterial Therapeutics to present at FDA workshop in the USA
• IBT | Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2025
• IBT | IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.
• IBT | IBT’s phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality
• IBT | Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024
• View more press releases Close

Redes sociais sobre Infant Bacterial Therapeutics

• Infant Bacterial Therapeutics na Wikipedia, Google News e Yahoo Finance
• Infant Bacterial Therapeutics na LinkedIn, Twitter e YouTube